-
1دورية أكاديمية
المؤلفون: Ou, Sai-Hong Ignatius, Govindan, Ramaswamy, Eaton, Keith D, Otterson, Gregory A, Gutierrez, Martin E, Mita, Alain C, Argiris, Athanassios, Brega, Nicoletta M, Usari, Tiziana, Tan, Weiwei, Ho, Steffan N, Robert, Francisco
المصدر: Journal of Thoracic Oncology. 12(1)
مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Lung, Lung Cancer, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Papillary, Crizotinib, Erlotinib Hydrochloride, Female, Follow-Up Studies, Humans, Lung Neoplasms, Lymphatic Metastasis, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Prognosis, Pyrazoles, Pyridines, Survival Rate, Tissue Distribution, Erlotinib, Phase I combination trial, MET inhibitor, EGFR inhibitor, Cardiorespiratory Medicine and Haematology, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/98r3c8d0Test
-
2دورية أكاديمية
المؤلفون: Li, Tianhong, LoRusso, Patricia, Maitland, Michael L, Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A, Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
المصدر: Journal of Hematology & Oncology. 9(1)
مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Lung, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Administration, Oral, Adult, Aged, Anaplastic Lymphoma Kinase, Antineoplastic Agents, Area Under Curve, Crizotinib, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Fatigue, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Nausea, Neoplasms, Protein Kinase Inhibitors, Pyrazoles, Pyridines, Receptor Protein-Tyrosine Kinases, Sulfones, Treatment Outcome, Triazines, Vomiting, Young Adult, ASP3026, ALK inhibitor, Phase I, Pharmacokinetics, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/59g2c6g2Test
-
3دورية أكاديمية
المؤلفون: Soo, Ross A., Tan, Eng Huat, Hayashi, Hidetoshi, Seto, Takashi, Lin, Chia-Chi, Ou, Sai-Hong Ignatius, Kim, Dong-Wan, Liu, Geoffrey, Abbattista, Antonello, Martini, Jean-Francois, Martini, Francois, Wong, Chew Hooi, Toffalorio, Francesca, Solomon, Benjamin J.
المساهمون: Kim, Dong-Wan
مصطلحات موضوعية: FUSION VARIANTS, SINGLE-ARM, OPEN-LABEL, INHIBITOR, REARRANGEMENT, MULTICENTER, CRIZOTINIB, GENE, ROS1, Lorlatinib, Asian, Non-small cell lung cancer, Tyrosine kinase inhibitor, Anaplastic lymphoma kinase
العلاقة: Lung Cancer, Vol.169, pp.67-76; https://hdl.handle.net/10371/184609Test; 000814794800003; 2-s2.0-85131633980; 165760
-
4دورية أكاديمية
المؤلفون: Zhu, Viola W., Lin, Yen-Ting, Kim, Dong-Wan, Loong, Herbert H., Nagasaka, Misako, To, Hao, Ang, Yvonne Li-En, Ock, Chan-Young, Tchekmedyian, Nishan, Ou, Sai-Hong Ignatius, Syn, Nicholas L., Reungwetwattana, Thanyanan, Lin, Chia-Chi, Soo, Ross A.
المساهمون: 김동완, Kim, Dong-Wan
مصطلحات موضوعية: CELL LUNG-CANCER, OPEN-LABEL, CRIZOTINIB, Lorlatinib, Expanded access, TKI-refractory, ALK, ROS1, NSCLC
العلاقة: Journal of Thoracic Oncology, Vol.15 No.9, pp.1484-1496; 113881; https://hdl.handle.net/10371/171813Test; 000566479100015; 2-s2.0-85086020844
-
5دورية أكاديمية
المؤلفون: Shaw, Alice Tsang, Riely, Gregory J., Bang, Yung-Jue, Kim, Dong-Wan, Camidge, David Ross, Solomon, Benjamin J., Varella-Garcia, Marileila, Iafrate, Anthony John, Shapiro, Geoffrey I., Usari, Tiziana, Wang, S. C., Wilner, Keith. D., Clark, Jeffrey W., Ou, Sai Hong Ignatius
المساهمون: 김동완, 방영주, Bang, Yung-Jue, Kim, Dong-Wan
مصطلحات موضوعية: crizotinib, non-small-cell lung cancer, ROS1, overall survival
العلاقة: Annals of Oncology, Vol.30 No.7, pp.1121-1126; 86820; https://hdl.handle.net/10371/171806Test; 2-s2.0-85069214430; https://www.sciencedirect.com/science/article/pii/S0923753419312372?via%3DihubTest; 000484369900018
الإتاحة: https://doi.org/10.1093/annonc/mdz131Test
https://hdl.handle.net/10371/171806Test
https://www.sciencedirect.com/science/article/pii/S0923753419312372?via%3DihubTest -
6دورية أكاديمية
المؤلفون: Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Nerve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Batas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.
المصدر: Yang , J C-H , Ou , S-H I , De Petris , L , Gadgeel , S , Gandhi , L , Kim , D-W , Barlesi , F , Govindan , R , Dingemans , A-M C , Crino , L , Lena , N , Popat , S , Ahn , J S , Dansin , E , Golding , S , Bordogna , W , Batas , B , Morcos , P N , Zeaiter , A & Shaw , A T 2017 , ' Pooled Systemic Efficacy and Safety Data from the Pivotal Phase ....
مصطلحات موضوعية: Alectinib, Non-small cell lung cancer, NP28673, NP28761, Pooled analysis, OPEN-LABEL, BRAIN METASTASES, CRIZOTINIB, CHEMOTHERAPY, INHIBITORS, CERITINIB, AF-001JP, DISEASE
الإتاحة: https://doi.org/10.1016/j.jtho.2017.06.070Test
https://cris.maastrichtuniversity.nl/en/publications/a48e959e-5703-41df-8135-ae933dedf88dTest -
7تقرير
المؤلفون: Zhang, Zhushan, Huang, Tai-Qin, Nepliouev, Igor, Zhang, Hengtao, Barnett, Adam, Rosenberg, Paul, Ou, Sai-Hong, Stiber, Jonathan
مصطلحات موضوعية: Crizotinib, Bradycardia, HCN4, Sinoatrial node, Non-small cell lung cancer
-
8دورية أكاديمية
المؤلفون: Ou, Sai-Hong I., Jaenne, P. A., Bartlett, C. H., Tang, Y., Kim, Dong-Wan, Otterson, G. A., Crino, L., Selaru, P., Cohen, D. P., Clark, J. W., Riely, G. J.
المساهمون: 김동완, Kim, Dong-Wan
مصطلحات موضوعية: treatment beyond disease progression, crizotinib, TKI, RECIST, oncogene addiction, ALK-positive NSCLC
العلاقة: Annals of Oncology, Vol.25 No.2, pp.415-422; 91759; http://hdl.handle.net/10371/165430Test; 2-s2.0-84893399587; https://www.sciencedirect.com/science/article/pii/S0923753419364853?via%3DihubTest; 000331269600019
الإتاحة: https://doi.org/10.1093/annonc/mdt572Test
http://hdl.handle.net/10371/165430Test
https://www.sciencedirect.com/science/article/pii/S0923753419364853?via%3DihubTest -
9
المؤلفون: Zhu, Viola W, Schrock, Alexa B, Bosemani, Thangavijayan, Benn, Bryan S, Ali, Siraj M, Ou, Sai-Hong Ignatius
المصدر: Lung Cancer: Targets and Therapy
مصطلحات موضوعية: resistance, fusion, crizotinib, T1151, lorlatinib, hemic and lymphatic diseases, Case Report, VKORC1L1
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::a8fc7fd1bad6bde542688a86e7eea86aTest
http://europepmc.org/articles/PMC6234987Test -
10دورية أكاديمية
المؤلفون: Zhang, Yongchang, Huang, Zhe, Zeng, Liang, Zhang, Xiangyu, Li, Yizhi, Xu, Qinqin, Yang, Haiyan, Lizaso, Analyn, Xu, Chunwei, Liu, Jun, Wang, Wenxian, Song, Zhengbo, Ou, Sai-Hong Ignatius, Yang, Nong
المصدر: NPJ Precision Oncology; 3/31/2022, Vol. 6 Issue 1, p1-4, 4p
مصطلحات موضوعية: DISEASE progression, CRIZOTINIB, NON-small-cell lung carcinoma, LUNGS, ADENOCARCINOMA